Business

The Cystic Fibrosis Foundation (CFF) has awarded Synspira Therapeutics up to $14 million in additional funding for development of two Synspira candidates including SNSP113, an inhaled polycationic glycopolymer for the treatment of CF. The foundation had previously awarded Synspira $8.55 million in 2017. SNSP113, which is currently in Phase 2 development, received … [Read more...] about Synspira gets additional CF Foundation funding for development of inhaled glycopolymer

Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company's Pharmaceutical Technology Center, will cost ₹495 (~$7) per pack. Cadila Healthcare Managing Director Sharvil Patel commented, "Our focus has always been on helping … [Read more...] about Zydus Cadila launches Forglyn formoterol / glycopyrrolate MDI in India

Teva Canada has launched the Aermony RespiClick fluticasone propionate DPI for the treatment of asthma, the company said. The inhaler will be available in 55 mcg, 113 mcg, and 232 mcg per actuation versions. According to the Health Canada web site, Aermony Respiclick was approved in 2017, the same year that ArmonAir Resplick fluticasone propionate was approved in … [Read more...] about Teva launches Aermony RespiClick in Canada

Starpharma said that it has raised A$45 million and expects to raise another A$5 million from Australian and international investors, with proceeds to be used for development of its SPL7013 astodrimer sodium nasal spray for the treatment of COVID-19 as well as for other candidates. The company recently announced that the nasal spray inactivated almost 100% of … [Read more...] about Starpharma raises A$45 million to be used in part for development of astodrimer sodium nasal spray for COVID-19

AZTherapies said that it has closed a $33.6 million Series C-1 financing that will fund regulatory and pre-commercial activities related to the company's ALZT-OP1 inhaled cromolyn/oral ibuprofen for Alzheimer’s disease and for development of other candidates. The financing round was led by Duopharma Biotech Berhad. In October 2019, AZTherapies announced that it had … [Read more...] about AZTherapies raises $33.6 million as Phase 3 trial of its inhaled Alzheimer’s therapy nears completion

Galecto said that it has completed a $64 million equity financing led by Soleus Capital that will be used to advance several candidates, including GB0139, a galectin-3 inhibitor DPI for the treatment of idiopathic pulmonary fibrosis (IPF). Specifically, the company said that funds will "support preparations for potential EU conditional approval of GB0139 in … [Read more...] about Galecto raises $64 million in preparation for potential approval of its inhaled galectin-3 inhibitor for IPF

Bharat Biotech and Precision Virologics have acquired the rights to a single dose intranasal COVID-19 vaccine developed at the Washington University School of Medicine in St. Louis, the companies said. The agreement gives Precision Virologics rights to the chimpanzee adenovirus-vectored vaccine in the US, Europe, and Japan and gives Bharat distribution rights in the … [Read more...] about Bharat Biotech and Precision Virologics license intranasal COVID-19 vaccine from Washington University in St. Louis